

.47

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FI	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/990,405 11/21/2001		11/21/2001	Alan L. Mueller	072827-1905	072827-1905 4028	
23620	7590	01/14/2003				
FOLEY &			EXAMINER			
402 WEST BROADWAY 23RD FLOOR				JARVIS, WILLIAM R A		
SAN DIEG		101		APTIBUT	DARRO MARANDO	
				. ART UNIT	PAPER NUMBER	
				1614		
			DATE MAILED: 01/14/2003			

Please find below and/or attached an Office communication concerning this application or proceeding.

7-4	Application No.	Applicant(s)					
Office Action Summary	09/990,405	MUELLER ET AL.					
omec Action Cummary	Examiner	Art Unit					
The MAILING DATE of this communication a	William R. Jarvis	1614					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) Responsive to communication(s) filed on 2	<u>3 September 2002</u> .						
2a) ☐ This action is FINAL. 2b) ☒	This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.							
4a) Of the above claim(s) <u>7-18</u> is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-6,19 and 20</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and	l/or election requirement						
Application Papers							
9)☐ The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14)⊠ Acknowledgment is made of a claim for dome	·						
a) ☐ The translation of the foreign language provisional application has been received. 15) ☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)					
U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Office	Action Summary	Part of Paper No. 9					

Application/Control Number: 09/990,405

Art Unit: 1614

1. Applicant's election of Group I, claims 1-16 and 18 in Paper No. 7 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). However, since claims 7-16 and 18 include compounds other than the elected specie, they are presently withdrawn from consideration.

Since prior art has been found that is applicable to the elected compound, no further search will be made unless this specie is deemed allowable. Applicant should note that in addition to the elected compound, the search of prior art included all of the compounds of claims 5 and 6. Accordingly, if the prior art employed in the obviousness rejection below is overcome, claims 5 and 6 would be allowable if written in independent form. Claims 1-6, 19, and 20 relate to the elected subject matter since they include the elected specie.

- 2. Claims 7-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in Paper No. 7.
- 3. Applicant should note that the correction of the misspelling of "patent" to "patient" in claims 1 and 3 has been made.
- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-6, 19, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jones et al (cited on the attached Form PTO-892). Jones teaches that applicant's elected

Application/Control Number: 09/990,405

Art Unit: 1614

compound exhibits antidepressant activity via its ability to antagonize reserpine-induced hypothermia in mice (ED_{10} 2mg/kg) and by inhibition of serotonin uptake at 10 μ g/ml (99%). See pages 161-163, particularly Table I, compound no. 28 on page 162. Applicant's claims differ in that they require a patient rather than a mouse. However, since elected specie demonstrated antidepressant activity through the antagonism of reserpine-induced hypothermia in mice and the inhibition of serotonin uptake in human platelets, one of ordinary skill in the pharmaceutical arts would have been motivated to treat depression in a patient therewith. Although the prior art does not disclose an effective amount for a patient, the administered amount is obvious since it is within the skill of the pharmaceutical artisan to determine the amount or dosage of a drug that provides the therapeutic effect most effective for treating the patient's condition while minimizing adverse side effects.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William R. Jarvis whose telephone number is 703-308-4613. The examiner can normally be reached on Monday, Tuesday, Thursday & Friday 7:00am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne C. Seidel can be reached on 703-308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

William R. Jarvis

Primary Examiner

Art Unit 1614